Shopping Cart 0
Cart Subtotal
USD 0

United States Central Venous Catheters Market Outlook to 2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 4995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 9990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 14985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

United States Central Venous Catheters Market Outlook to 2023

Summary

GlobalData's new report, "United States Central Venous Catheters Market Outlook to 2023", provides key market data on the United States Central Venous Catheters market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments-Antimicrobial Central Venous Catheters, Non Antimicrobial Central Venous Catheters and PICC (Peripherally Inserted Central Catheter) Lines.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

Market size and company share data for Central Venous Catheters market segments-Antimicrobial Central Venous Catheters, Non Antimicrobial Central Venous Catheters and PICC (Peripherally Inserted Central Catheter) Lines.

Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.

2016 company shares and distribution shares data for each of the market segments.

Global corporate-level profiles of key companies operating within the United States Central Venous Catheters market.

Key players covered include Teleflex Inc, C. R. Bard Inc, Edwards Lifesciences Corp and B. Braun Melsungen AG.

Reasons to buy

Develop business strategies by identifying the key market segments poised for strong growth in the future.

Develop market-entry and market expansion strategies.

Design competition strategies by identifying who-stands-where in the market.

Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 What Is This Report About? 5

2.2 Central Venous Catheters Market Segmentation 5

2.3 Definitions of Markets Covered in the Report 6

3 Central Venous Catheters Market, United States 7

3.1 Central Venous Catheters Market, United States, Revenue ($m), 2009-2016 7

3.2 Central Venous Catheters Market, United States, Revenue ($m), 2016-2023 9

3.3 Central Venous Catheters Market, United States, Volume (Units), 2009-2016 11

3.4 Central Venous Catheters Market, United States, Volume (Units), 2016-2023 13

3.5 Central Venous Catheters Market, United States, Average Price ($), 2009-2023 15

3.6 Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), 2015-2016 16

3.7 Central Venous Catheters Market, United States, Company Share by Revenue ($m), 2016 17

4 Overview of Key Companies in United States, Central Venous Catheters Market 19

4.1 Teleflex Inc 19

4.1.1 Company Overview 19

4.2 C. R. Bard Inc 19

4.2.1 Company Overview 19

4.3 Edwards Lifesciences Corp 19

4.3.1 Company Overview 19

4.4 B. Braun Melsungen AG 20

4.4.1 Company Overview 20

4.5 Smiths Medical 20

4.5.1 Company Overview 20

5 Central Venous Catheters Market Pipeline Products 21

6 Financial Deals Landscape 22

6.1 Debt Offerings 22

6.1.1 PAVmed Raises USD5 Million in Private Placement of Notes and Warrants 22

6.1.2 Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 23

6.1.3 Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 24

6.1.4 Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 25

6.1.5 Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 26

6.1.6 Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 27

6.1.7 Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 28

6.1.8 Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 29

6.1.9 Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 30

6.1.10 Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 31

6.1.11 Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 33

6.2 Equity Offerings 35

6.2.1 Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 35

6.2.2 Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 37

6.2.3 PAVmed to Raise USD10.4 Million in Private Placement of Shares upon Exercise of Warrants 39

6.2.4 PAVmed Raises Additional Funds in Second and Final Tranche of Private Placement of Units 40

6.2.5 PAVmed Raises USD1.5 Million in First Tranche of Private Placement of Units 41

6.2.6 PAVmed to Raise USD5.3 Million in Private Placement of Shares upon Exercise of Warrants 42

7 Recent Developments 43

7.1 Corporate Communications 43

7.1.1 Apr 23, 2017: BD Announces Appointment Of Tom Polen As President 43

7.1.2 Mar 21, 2017: PAVmed Names Medical Device Industry Veteran Dennis M. McGrath as Chief Financial Officer 43

7.1.3 Feb 23, 2017: Teleflex Announces Benson Smith to Retire as Chief Executive Officer at End of 2017; Liam Kelly to Succeed Smith as Chief Executive Officer 44

7.1.4 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors 44

7.2 Financial Announcements 45

7.2.1 May 22, 2017: PAVmed Reports First Quarter 2017 Financial Results and Provides Business Update 45

7.2.2 May 10, 2017: ICU Medical Announces First Quarter 2017 Results 45

7.2.3 May 04, 2017: Teleflex Reports First Quarter 2017 Results 46

7.2.4 May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter 47

7.2.5 Apr 03, 2017: Retractable Technologies Reports Results for the Year 2016 49

7.2.6 Mar 01, 2017: ICU Medical Announces Fourth Quarter and Fiscal Year 2016 Results 49

7.2.7 Feb 23, 2017: Teleflex Reports Fourth Quarter and Full Year 2016 Results; Provides 2017 Guidance 50

7.2.8 Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter 51

7.2.9 Nov 14, 2016: Retractable Technologies Reports Results as of September 30, 2016 52

7.2.10 Nov 09, 2016: ICU Medical Announces Third Quarter 2016 Results 53

7.2.11 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance 54

7.2.12 Oct 27, 2016: Teleflex Reports Third Quarter 2016 Results 55

7.2.13 Aug 16, 2016: PAVmed Announces Second Quarter 2016 Financial Results and Provides Business Update 57

7.2.14 Aug 16, 2016: Retractable Technologies Reports Results as of June 30, 2016 58

7.2.15 Aug 08, 2016: ICU Medical Announces Second Quarter 2016 Results 59

7.2.16 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter 59

7.2.17 Jul 28, 2016: Teleflex Reports Second Quarter 2016 Results 61

7.3 Government and Public Interest 62

7.3.1 Jun 06, 2017: BD Releases 2016 Sustainability Report 62

7.3.2 Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management 62

7.4 Legal And Regulatory 63

7.4.1 Mar 21, 2017: Retractable Technologies Announces Litigation Updates 63

7.4.2 Dec 02, 2016: Retractable Technologies Reports on Fifth Circuit's Opinion 63

8 Appendix 64

8.1 Research Methodology 65

8.1.1 Coverage 65

8.1.2 Secondary Research 65

8.1.3 Primary Research 66

8.1.4 Company Share Analysis 66

8.1.5 Distribution Share Analysis 66

8.1.6 Benchmarking 67

8.2 GlobalData Consulting 67

8.3 Contact Us 68

8.4 Disclaimer 68


List Of Figure

1.2 List of Figures

Figure 1: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 7

Figure 2: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 9

Figure 3: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016 11

Figure 4: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023 13

Figure 5: Central Venous Catheters Market, United States, Company Share (%) 2016 17


List Of Table

1.1 List of Tables

Table 1: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 8

Table 2: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 10

Table 3: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016 12

Table 4: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023 14

Table 5: Central Venous Catheters Market, United States, Average Price ($), Historic, 2009-2016 15

Table 6: Central Venous Catheters Market, United States, Average Price ($), Forecast, 2016-2023 15

Table 7: Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 16

Table 8: Central Venous Catheters Market, United States, Company Share by Revenue ($m), USD Constant, 2016 18

Table 9: Central Venous Catheters Market Pipeline Products 21

Table 10: PAVmed Raises USD5 Million in Private Placement of Notes and Warrants 22

Table 11: Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 23

Table 12: Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 24

Table 13: Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 25

Table 14: Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 26

Table 15: Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 27

Table 16: Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 28

Table 17: Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 29

Table 18: Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 30

Table 19: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 31

Table 20: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 33

Table 21: Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 35

Table 22: Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 37

Table 23: PAVmed to Raise USD10.4 Million in Private Placement of Shares upon Exercise of Warrants 39

Table 24: PAVmed Raises Additional Funds in Second and Final Tranche of Private Placement of Units 40

Table 25: PAVmed Raises USD1.5 Million in First Tranche of Private Placement of Units 41

Table 26: PAVmed to Raise USD5.3 Million in Private Placement of Shares upon Exercise of Warrants 42

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Drug Delivery Devices, Central Venous Catheters, Needle Free Injections, Infusion Systems, Metered Dose Inhaler Devices, Value (USD), Volume (units), Revenues, Historic Revenues, Forecast Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Pfizer Inc, Merck Co Inc, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, INJEX-Equidyne Systems, Bioject Medical Technologies Inc , Antares Pharma Inc, PharmaJet Inc, MK Global Co., The European Pharma Group, Hospira Inc, Becton Dickinson and Co, Baxter International Inc, Fresenius Kabi AG, Medtronic plc, B. Braun Melsungen AG, Terumo Corp, Smiths Medical, Nipro Corp, JMS Co Ltd


Companies

Teleflex Inc

C. R. Bard Inc

Edwards Lifesciences Corp

B. Braun Melsungen AG

Smiths Medical